利用四个欧洲中毒中心数据推进消遣性药物及新型精神活性物质的中毒监测
该回顾性观察研究合并了德国弗赖堡、荷兰、瑞典和瑞士四个欧洲中毒中心2021年电子病例报告中的消遣性药物中毒数据,常见消遣性药物采用汇总数据、新型精神活性物质采用逐例数据。2021年消遣性药物中毒占中毒中心来电的2.0%,涉及3,705例患者、4,380次药物暴露,其中常见消遣性药物3,708次、新型精神活性物质672次。常见消遣性药物中毒率每百万居民48(弗赖堡)至145(瑞典),新型精神活性物质中毒率每百万居民2(瑞士)至29(荷兰)。研究显示中毒中心数据可提供暴露、使用者特征和症状的详细洞察,可用于跨国综合监测。
要点
- 2021年消遣性药物中毒占四个欧洲中毒中心来电的2.0%,涉及3,705例患者、4,380次药物暴露。
- 常见消遣性药物暴露以安非他明(22%)、可卡因(20%)、含delta-9-四氢大麻酚制剂(20%)和3,4-亚甲二氧基甲基安非他明(13%)最常见。
- 新型精神活性物质以卡西酮类(43%)、设计苯二氮䓬类(28%)和苯乙胺类(13%)最常见。
- 卡西酮类中毒症状为心动过速(35%)和高血压(13%),设计苯二氮䓬类以嗜睡最突出(38%)。
- 新型精神活性物质使用者中男性占67%,55%为18至30岁,8%为未成年人(<18岁)。
适用人群与场景
- 2021年向德国弗赖堡、荷兰、瑞典和瑞士四个欧洲中毒中心报告的消遣性药物中毒患者,包括11种常见消遣性药物和新型精神活性物质中毒。
研究设计与关键结果
- 研究为回顾性观察研究,四个欧洲中毒中心(德国弗赖堡、荷兰、瑞典、瑞士)参与,收集2021年11种常见消遣性药物的汇总数据和新型精神活性物质的逐例数据。
- 2021年消遣性药物中毒占中毒中心来电的2.0%,涉及3,705例患者、4,380次药物暴露,其中常见消遣性药物3,708次、新型精神活性物质672次。
- 每百万居民常见消遣性药物中毒率从48(弗赖堡)到145(瑞典)不等;新型精神活性物质中毒率从2(瑞士)到29(荷兰)不等。
- 常见消遣性药物暴露最常见为安非他明(22%)、可卡因(20%)、含delta-9-四氢大麻酚制剂(20%)和3,4-亚甲二氧基甲基安非他明(13%)。
- 新型精神活性物质最常见类别为卡西酮类(43%)、设计苯二氮䓬类(28%)和苯乙胺类(13%)。
- 卡西酮类中毒后症状为心动过速(35%)和高血压(13%);设计苯二氮䓬类中毒后嗜睡最突出(38%)。
- 新型精神活性物质使用者中男性占67%,55%年龄在18至30岁,8%为未成年人(<18岁)。
证据类型、等级与局限
- 证据类型:回顾性观察研究。
- 局限:中毒中心数据低估了药物相关健康事件的总体发生率。
对床旁实践的改变
- 作者认为,中毒中心数据提供全国覆盖,不同于药物相关急诊就诊等其他数据源。
- 作者认为,中毒中心数据可提供常见消遣性药物和新型精神活性物质暴露、使用者特征和症状的详细洞察,可用于跨国层面的药物相关健康事件综合监测。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Common recreational drugs and new psychoactive substances pose challenges to public health. This study investigated the feasibility of merging cases of recreational drug poisoning reported to European poison centres.
METHODS: Four European poison centres (Freiburg, Germany; the Netherlands; Sweden and Switzerland) collaborated in a retrospective, observational study. We collected aggregated data on poisonings with 11 common recreational drugs and case-by-case data on poisonings with new psychoactive substances in 2021 by using anonymized data from electronic case reports.
RESULTS: In 2021, 2.0% of the poison centre calls involved poisonings with recreational drugs. The poison centres were contacted about 3,705 patients, involving 4,380 drug exposures, of which 3,708 were common recreational drugs, and 672 were new psychoactive substances. Per million inhabitants, the poisoning rate with common recreational drugs varied between 48 (Freiburg) and 145 (Sweden). Poisonings with amfetamine (22%), cocaine (20%), all delta-9-tetra-hydrocannabinol-containing preparations (20%), and 3,4-methylenedioxymetamfetamine (13%) exposures were most frequent. The poisoning rate per million inhabitants with new psychoactive substances varied between two (Switzerland) and 29 (Netherlands). Cathinones (43%), designer benzodiazepines (28%), and phenethylamines (13%) were the most commonly involved new psychoactive substance classes. Symptoms following cathinone poisoning were tachycardia (35%) and hypertension (13%), while following designer benzodiazepines, somnolence was most prominent (38%). The majority of users of new psychoactive substances were male (67%), 55% were between 18 and 30 years, and 8% involved minors (<18 years).
DISCUSSION: This study showed the feasibility of merging data on recreational drug poisoning collected by poison centres in four countries. Despite underestimating the overall incidence of drug-related health incidents, poison centre data offers national coverage, unlike other data sources, such as drug-related emergency department visits.
CONCLUSION: This multi-centre, multi-national study reported a substantial annual number of recreational drug poisonings, with a variable proportion of new psychoactive substances. It shows that poison centre data offers detailed insights into exposures to common recreational drugs and new psychoactive substances, user characteristics, and symptoms. It can be used for comprehensive monitoring of drug-related health incidents on a multi-national level.
参考来源
- Kader A, Hermanns-Clausen M, van Riel A, et al. Advancing toxicovigilance of recreational drugs, including new psychoactive substances, by using data from four European poison centres. Clin Toxicol (Phila). 2024. PMID: 39635984. doi:10.1080/15563650.2024.2430311
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。